Document:

EX-4.20

 Exhibit 4.20 

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE
SECURITIES ACT, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL
APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS. THERE IS NO AND THERE IS NOT EXPECTED TO BE A PUBLIC MARKET FOR THE SHARES OF COMMON STOCK ISSUABLE UPON ANY EXERCISE HEREOF. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE
FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. 
 WARRANT TO PURCHASE 

SHARES OF COMMON STOCK OF 

AMEDICA CORPORATION 
  

			
	Warrant No. CDC-            	 	Issue Date:                 , 2013

 This certifies that, for value received, TGP Securities, Inc., 6 Glendale Rd., Summit, NJ 07901 (the
“Holder”), is entitled to purchase from Amedica Corporation, a Delaware corporation with offices at 1885 West 2100 South, Salt Lake City, UT 84119 (the “Company”), ___________________
(            ) shares of the Company’s common stock, $0.01 par value per share (“Common Stock”), as such number and class of securities may be adjusted in accordance
with the terms of Section 4 below, for the Stated Purchase Price (defined below), at any time up to and including 5:00 p.m. (New York City time) on the Warrant Expiration Date (as defined below) in accordance with the terms hereof.
“Stated Purchase Price” shall mean the purchase price to be paid upon exercise of this Warrant in accordance with the terms hereof, which price initially shall be $2.20 per share of Common Stock. The Stated Purchase Price shall be
subject to adjustment from time to time pursuant to the provisions of Section 4 below. “Warrant Expiration Date” means 5:00 p.m., New York City time, on the fifth anniversary of the original date of issuance of the Warrant. If
pursuant to the above the Warrant Expiration Date would be a Saturday, Sunday or legal holiday in the State of Utah, then the Warrant Expiration Date shall be the next succeeding date that is not a Saturday, Sunday or legal holiday. 

1. Exercise. 
 (a)
Manner of Exercise. This Warrant may be exercised at any time or from time to time for all or any part of the number of shares of Common Stock (or other securities) then purchasable upon its exercise (the “Shares”); provided,
however, that this Warrant shall be void and all rights represented hereby shall cease unless exercised before the end of the Warrant Expiration Date. In order to exercise this Warrant, in whole or in part, Holder will deliver to the Company at its
principal executive offices, or at such other office as the Company may designate by notice in writing, (i) this Warrant, (ii) a written notice of Holder’s election to exercise this Warrant substantially in the form of Exhibit
A attached hereto (the “Notice of Exercise”), and 

 (iii) any documents required pursuant to Section 7 hereof, and shall pay to the Company in
cash, by a certified or cashier’s check drawn on a United States Bank made payable to the order of the Company, or by wire transfer of funds to a bank account designated by the Company, an amount equal to the aggregate Stated Purchase Price for
all Shares as to which this Warrant is exercised. 
 (b) Net Exercise. 

(1) In lieu of exercising this Warrant by payment in cash, or by check or wire transfer, the Holder may elect to receive Shares equal to the
value of this Warrant (or the portion thereof being exercised), at any time after the date hereof and before the end of the Warrant Expiration Date, by surrender of this Warrant at the principal executive office of the Company, together with the
Notice of Exercise in the form annexed hereto, in which event the Company will issue to the Holder a number of Shares computed in accordance with the following formula: 
  

									
		  	X    =	  	 Y x (A-B)
	  		  	
		  		  	A	  		  	

  

							
	Where,	  	X	  	=	  	the number of Shares to be issued to Holder pursuant to this net exercise;
		  	Y	  	=	  	the number of Shares for which the net exercise election is made;
		  	A	  	=	  	the fair market value of one Share at the time the net exercise election is made; and
		  	B	  	=	  	the Stated Purchase Price (as adjusted at the date of the net exercise election is made).

 (2) For purposes of this Section 1(b), the fair market value of a Share and the effectiveness of the
exercise of this Warrant are determined as follows: 
 (i) if the exercise is in connection with an initial public offering, and if the
Company’s registration statement relating to such offering has been declared effective by the Securities and Exchange Commission, then the fair market value shall be the initial “Price to Public” specified in the final prospectus with
respect to the offering (net of applicable underwriting commissions), and such exercise shall be effected upon the date of such initial public offering, subject to due, proper and prior surrender of this Warrant and the closing of the initial public
offering; 
 (ii) if the exercise is in connection with a Change of Control, then the fair market value shall be the value received by the
holders of Shares pursuant to the Change of Control for each share of such securities, and the exercise shall be effective upon the closing of such Change of Control, subject to due, proper and prior surrender of this Warrant and the closing of the
Change of Control; or 
 (iii) if the exercise is other than in connection with subsections (i) or (ii) above and the Shares
are traded on a securities exchange or through the Nasdaq Global Market, the value shall be deemed to be the average of the closing prices of the securities on 

  
 - 2 - 

 
such exchange over the thirty (30) day period ending three (3) days prior to the net exercise election; or 

(iv) if the exercise is other than in connection with subsections (i) or (ii) above and the Shares are traded over-the-counter,
the value shall be deemed to be the average of the closing bid or sale prices (whichever is applicable) over the thirty (30) day period ending three (3) days prior to the net exercise; or 

(v) if the exercise is other than in connection with subsections (i) or (ii) above and the Shares are not traded on the
over-the-counter market or on an exchange, the fair market value shall be determined in good faith by the Company’s Board of Directors (the “Board”). 

For purposes of this Warrant, A “Change of Control” shall mean any acquisition of capital stock of the Company, directly or indirectly, any merger,
tender offer, recapitalization or asset sale pursuant to which the Company’s stockholders immediately prior to such transaction hold less than 50% of the voting securities of the surviving corporation immediately after such transaction or the
majority of the assets of the Company are transferred or sold, except that any internal restructuring or re-organization of the Company that does not change the effective ultimate ownership of the Company shall not be deemed a Change of Control.

 (c) Issuance of Shares. Upon receipt of the documents and payments described in Section 1(a), the Company shall, as promptly
as practicable, execute or cause to be executed, and deliver to Holder a certificate or certificates representing the aggregate number of full Shares issuable upon such exercise, together with an amount in cash in lieu of any fraction of a Share, as
hereinafter provided. If this Warrant shall have been exercised in part, the Company shall, at the time of delivery of said certificate or certificates, deliver to the Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased
Shares, which new Warrant shall in all other respects be identical with this Warrant. 
 2. Reservation of Shares. The Company
covenants that it will at all times until the Warrant Expiration Date reserve and keep available out of its authorized and unissued Common Stock (or other securities of the Company, as applicable), solely for the purpose of issue upon exercise of
this Warrant such number of shares of Common Stock (or other securities of the Company, as applicable) as shall then be issuable upon the exercise of this Warrant. 

3. Loss or Mutilation. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant (including a reasonably detailed affidavit with respect to the circumstances of any loss, theft or destruction of such Warrant), and, in the case of any such mutilation, upon surrender and cancellation of this Warrant, the Company, at
Holder’s expense, will execute and deliver, in lieu hereof, a new Warrant of like tenor. 
 4. Adjustments to Shares and Stated
Purchase Price. 
 (a) If the Company at any time after the date hereof through the Warrant Expiration Date subdivides (by any stock
split, stock dividend, recapitalization or otherwise) its outstanding shares of Common Stock into a greater number of shares, the Stated Purchase Price 

  
 - 3 - 

 
in effect immediately prior to such subdivision will be proportionately reduced and the number of shares issuable upon exercise of this Warrant will be proportionately increased, and if the
Company at any time combines (by reverse stock split, recapitalization or otherwise) its outstanding shares of Common Stock into a smaller number of shares, the Stated Purchase Price in effect immediately prior to such combination will be
proportionately increased and the number of shares issuable upon exercise of this Warrant will be proportionately decreased. If the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise,
change any of the securities as to which purchase rights under this Warrant exist into the same or a different number of securities of any other class or classes, this Warrant shall thereafter represent the right to acquire such number and kind of
securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such combination, reclassification, exchange, subdivision or other
change. 
 (b) When any adjustment is required to be made in the number or kind of Shares purchasable upon exercise of this Warrant, or the
Stated Purchase Price, the Company shall promptly notify the Holder in writing of such event, of the number and description of Shares thereafter purchasable upon exercise of this Warrant, and of the revised Stated Purchase Price. 

5. Fractional Shares. No fractional Shares shall be issued upon the exercise of this Warrant, but, instead of any fraction of a Share
which would otherwise be issuable, the Company shall pay a cash adjustment in respect of such fraction in an amount equal to the same fraction of the fair market value per share of Common Stock (or other securities, as applicable) as of the close of
business on the date of the notice required by Section 1 above, determined in good faith by the Board. 
 6. Warrant Not
Transferable. This Warrant is only exercisable by Holder and it is not transferable to any other party. 
 7. Agreements. As a
condition precedent to any exercise of this Warrant, Holder understands and agrees that it may be required to execute certain documents and agreements (in Company standard form) relating to the purchase and sale of Shares, as well as right of first
refusal, co-sale and voting rights agreements, if applicable, which all other purchasers of the same class of shares are required to execute. Upon the execution and delivery of such documents and agreements, Holder will become a party to, and bound
by, such agreements, as so amended or restated, as to the securities acquired upon exercise of this Warrant. 
 8. Holder’s
Representations and Warranties. Holder, by acceptance hereof, hereby represents as follows: 
 (a) Investment Purpose. The right
to acquire Shares (and the Shares) issuable upon exercise of the Holder’s rights contained herein will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of
selling or engaging in any public distribution of the same except pursuant to a registration or exemption. 

  
 - 4 - 

 (b) Private Issue. The Holder understands (i) that the Shares issuable upon exercise
of this Warrant are not registered under the Securities Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the registration and qualifications requirements
thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations of Holder herein. 
 (c)
Financial Risk. The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 

(d) Risk of No Registration. The Holder understands that if the Company does not register pursuant to Section 12 of the Securities
Exchange Act of 1934, as amended (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the Securities Act is not in effect when it desires to
sell the securities issuable upon exercise of this Warrant, it may be required to hold such securities for an indefinite period. The Holder also understands that any sale of securities issued or issuable hereunder which might be made by it in
reliance upon Rule 144 under the Securities Act may be made only in accordance with the terms and conditions of that Rule. 
 (e)
Accredited Investor. Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D, promulgated under the Securities Act, as presently in effect. 

9. Company’s Representations and Warranties. The Company hereby represents and warrants to Holder as follows: 

(a) Due Authorization. This Warrant has been duly authorized, executed and delivered by the Company and constitutes the valid and
binding obligation of the Company, enforceable in accordance with its terms. 
 (b) Status of Shares; Price. The Shares purchased by
Holder upon any exercise of this Warrant in accordance with its terms will be, when issued by the Company, duly authorized, validly issued, fully paid in compliance with applicable securities laws (assuming the accuracy of the Holder’s
representations and warranties herein) and nonassessable. 
 10. Holder Not Deemed Stockholder. Holder will not, as such, be entitled
to vote or to receive dividends or be deemed the holder Shares that may at any time be issuable upon exercise of this Warrant for any purpose whatsoever, nor shall anything contained herein be construed to confer upon Holder, as such, any of the
rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights, until Holder shall have exercised this
Warrant and been issued Shares in accordance with the provisions hereof. Subject to applicable law, any right not specifically granted hereunder to Holder is hereby disclaimed by the Company. 

11. Modification of Warrant. This Warrant shall not be modified, supplemented or altered in any respect except with the consent in
writing of the Holder and the Company. 

  
 - 5 - 

 12. Notices. All demands, notices and communications relating to this Warrant shall be in
writing and (i) sent by registered or certified mail, postage prepaid, return receipt requested, (ii) hand delivered, (iii) sent by express mail or other reasonable overnight delivery service, or (iv) sent by telecopy, as follows
(or to such other address as to which notice may be given hereunder by the party entitled to receipt of notice): 
 If to the Company: 

Amedica Corporation 
 1885 West
2100 South 
 Salt Lake City, UT 84119 
  

	 	Attention:	Kevin Ontiveros 

	 	    	Chief Legal Officer 

	 	Telephone:	(801) 839-3500 

	 	Telecopy:	(801) 839-3605 

 13. Governing Law. This Warrant shall be governed by, and construed in
accordance with, the laws of the State of Delaware, without regard to conflict of law principles. 
 14. Jurisdiction. Each of the
Company and the Holder hereby irrevocably submits to the jurisdiction of any Utah State or Federal court sitting in Salt Lake City in any action or proceeding arising out of or relating to this Warrant, and each of the Company and the Holder hereby
irrevocably agrees that all claims in respect of such action or proceeding may be heard and determined in such Utah State court or in such Federal court. Each of the Company and the Holder hereby irrevocably waives, to the fullest extent permitted
under applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding. Each of the Company and the Holder irrevocably consents, to the fullest extent permitted under applicable law, to the service of any summons
and complaint and any other process by the mailing of copies of such process to them at their respective address specified in Section 12 hereof. Each of the Company and the Holder hereby agrees, to the fullest extent permitted under applicable
law, that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

15. Waiver of Jury Trial. TO THE FULLEST EXTENT PERMITTED UNDER APPLICABLE LAW, EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS WARRANT. 

16. Miscellaneous. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the
terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. 

[signature page follows] 

  
 - 6 - 

 IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Shares of Common Stock to be
duly executed as of August 30, 2013. 
  

			
	AMEDICA CORPORATION
		
	By:	 	 
	 Name:
 Title:
	 	 Eric K. Olson
 Chief Executive
Officer

  
 - 7 - 

 EXHIBIT A 

EXERCISE FORM 
 (To be signed only
on exercise of Warrant) 
 Amedica Corporation, 
 1885 West 2100
South 
 Salt Lake City, UT 84119 
 The
undersigned hereby irrevocably elects to exercise the right to purchase represented by the within Warrant for, and to purchase thereunder, _______ shares of the stock provided for therein, and requests that certificates for such shares be issued in
its name, and, if said number of shares shall not be all the shares purchasable thereunder, that a new Warrant for the balance remaining of the shares be issued to it. 

In connection with this exercise, attached please find all documents required to be signed by the undersigned as per the terms of the Warrant,
all duly executed by the undersigned and binding thereupon. 
  

			
		
	Name of Holder:	 	 
		
	Signature:	 	 
		
	Position of Signatory:	 	 
		
	Date:	 	 

  
  
  

  
 - 8 - 

 CDC-__A 

AMENDMENT TO 
 WARRANT TO
PURCHASE SHARES OF COMMON STOCK OF 
 AMEDICA CORPORATION 

This Amendment to Warrant to Purchase Shares of Common Stock (this “Amendment”) dated as of December ___ 2013, is made
by and between Amedica Corporation, a Delaware corporation (the “Company”), and the undersigned, TGP Securities, Inc. (the “Warrant Holder”), and it hereby amends that certain Warrant to Purchase
Shares of Common Stock of the Company originally issued as of [August 30/September 19], 2013 (the “Existing Warrant”), in connection with the Company’s offering of 100 units wherein each unit consisted of 50,000 shares
of the Company’s Series F Convertible Preferred Stock and one five year warrant to acquire 25,000 shares of the Company’s common stock exercisable at $1.00 per share. 

NOW, THEREFORE, in consideration of the mutual promises contained herein, and the benefits to be derived by each party hereunder, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Warrant Holder, intending to be legally bound, hereby agree to amend the Existing Warrant, as set forth below and hereby agree as
follows: 
 AGREEMENT: 

Section 1. Amendment to Section 4 – Adjustments to Shares and Stated Purchase Price. Section 4 of the Existing Warrant is
hereby amended by inserting an additional paragraph immediately following Section 4(b) as follows: 
 “(c) If the
Company at any time after the date hereof through the Warrant Expiration Date issues or sells any stock or other security (other than warrants or options to subscribe for or purchase shares of Common Stock or Preferred Stock granted to employees or
consultants to the Company or securities (including warrants) issued by the Company in connection with the closing of an initial public offering of Common Stock, any strategic collaboration, license, or other similar transaction, or any senior
credit facility) that is at any time and under any circumstances, directly or indirectly convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire any shares of Common Stock or Preferred Stock (the
“Convertible Securities”), for a consideration per share less than the Stated Purchase Price then in effect or for which the Convertible Securities have a conversion rate of less than the Stated Purchase Price then in effect, then
the Stated Purchase Price in effect immediately prior to such issuance or sale will be reduced, concurrently with such issue, to the consideration per share received by the Company for such issuance or sale. This Section 4(c) shall terminate and be
of no further force or effect, and the Holder of the Warrant shall not be entitled to any adjustment in the Stated Purchase Price upon and following the closing of an initial public offering of Common Stock.” 

 Section 2. No Further Amendments. Except as expressly amended hereby, the Existing Warrant
is in all respects ratified and confirmed and all the terms, conditions, and provisions thereof shall remain in full force and effect. 

Section 3. Effect of Amendment. This Amendment shall form a part of the Existing Warrant for all purposes, and each party thereto and
hereto shall be bound hereby. From and after the execution of this Amendment by the parties hereto, any reference to the Existing Warrant shall be deemed a reference to the Existing Warrant as amended hereby. 

Section 4. Headings. The descriptive headings contained in this Amendment are included for convenience of reference only and shall not
affect in any way the meaning or interpretation of this Amendment. 
 Section 5. Counterparts; Facsimiles. This Amendment may be
executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. A
facsimile or other electronically transmitted signature on this Amendment is as valid as an original signature. 
 Section 6. Governing
Law. This Amendment and the rights and duties of the parties hereto shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware. 

IN WITNESS WHEREOF, the Company and Warrant Holder have caused this Amendment to Warrant to Purchase Shares of Common Stock of Amedica
Corporation to be executed and delivered as of the date first written above by their respective officers thereunto duly authorized. 
  

									
	THE COMPANY:	 		 	WARRANT HOLDER:
			
	AMEDICA CORPORATION	 		 	TGP SECURITIES, INC.
					
	By:	 	 	 		 	By:	 	 
		 	 Name: Eric K. Olson
 Title:
  President and CEO
	 		 		 	 Print/Type Name:
 Print/Type
Title:EX-10.12

 Exhibit 10.12 
 SEVERANCE AND CHANGE IN CONTROL AGREEMENT 
 This Severance and Change in
Control Agreement (the “Agreement”) is entered into as of the [•] day of [•], [•] by and between Amedica Corporation, a Delaware corporation (the “Company”) and [•] (the “Executive”). 

WHEREAS, the Executive is [•] of the Company; 
 WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company; 

WHEREAS, the Executive desires to enter into this Agreement to provide the Executive with certain financial protection in the event that
his employment terminates under certain conditions following a change in control of the Company; and 
 WHEREAS the Board of
Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive agree as follows: 

1. Definitions. 
 (a)
Cause. For purposes of this Agreement, “Cause” means: (i) the Executive’s commission of a felony (other than through vicarious liability or through a motor vehicle offense); (ii) the Executive’s material
disloyalty or dishonesty to the Company; (iii) the commission by the Executive of an act of fraud, embezzlement or misappropriation of funds; (iv) a material breach by the Executive of any material provision of this Agreement or any other
agreement to which the Executive and the Company are party, which breach is not cured within thirty (30) days after delivery to the Executive by the Company of written notice of such breach; or (v) the Executive’s refusal to carry out
a lawful written directive from the Board which is within Executive’s normal Company duties. Any determination of Cause will be made by a majority of the Board voting on such determination. 

(b) Change in Control. For purposes of this Agreement, a “Change in Control” shall mean: (i) any “person”
(as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Act”)) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of
the Company representing 50% or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose the Company or its Affiliates or any employee benefit plan of the Company) pursuant to a
transaction or a series of related transactions of which the Board does not approve; (ii) a merger or consolidation of the Company, whether or not approved by the Board, other than a merger or consolidation which would result in the voting
securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the
total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation outstanding immediately 

  

Initials      

 
after such merger or consolidation; or (iii) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of the Company’s
assets. For purposes of this Agreement, “Change in Control” shall be interpreted in a manner, and limited to the extent necessary, so that it will not cause adverse tax consequences for either party with respect to Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”), and the treasury regulations issued thereunder or any guidance issued by the IRS concerning the interpretation or applicability of Section 409A of the Code. 

(c) Disability. For purposes of this Agreement, “Disability” means the inability of the Executive to perform the
principal functions of his duties due to a physical or mental impairment, but only if such inability has lasted or is reasonably expected to last for at least sixty (60) consecutive days or an aggregate of one hundred twenty (120) days
during any twelve-month period. Whether the Executive has a Disability will be determined by a majority of the Board based on evidence provided by one or more physicians selected by the Board and approved by Executive, which approval shall not be
unreasonably withheld. 
 (d) Good Reason. For purposes of this Agreement, “Good Reason” shall mean, without
the Executive’s consent: (i) a change in the principal location at which the Executive performs his duties for the Company to a new location that is at least fifty (50) miles from the prior location; or (ii) a material change in
the Executive’s compensation or authority, functions, duties or responsibilities, which would cause his position with the Company to become of less responsibility, importance or scope than his position on the date of this Agreement or as of any
subsequent date prior to the Change in Control, provided, however, that such material change is not in connection with the termination of the Executive’s employment by the Company for any reason. 

2. Change in Control. Immediately upon the consummation of a Change in Control all outstanding options, restricted stock and other similar rights
held by the Executive shall become one hundred percent (100%) vested. 
 3. Severance Compensation. In the event that, within a
period of one (1) year following the consummation of a Change in Control, the Executive’s employment with the Company is terminated by the Company other than for Cause (but not including termination due to the Executive’s death or
Disability), or terminated by the Executive for Good Reason, then, within ten (10) days of the applicable termination date, the Executive shall be entitled to, in addition to any amounts due to the Executive for services rendered prior to the
termination date, a lump sum payment from the Company of an amount equal to two (2) times the Executive’s highest Annual Salary with the Company during the preceding three-year period, including the year of such termination (the
“Severance Compensation”). For purposes of this Agreement, “Annual Salary” shall mean the Executive’s annual base salary and bonus payments (measured on the Company’s 12-month fiscal year period), excluding
reimbursements and amounts attributable to stock options and other non-cash compensation. 

  

Initials      

 4. Section 280G. 
 (a) In the event that Executive becomes entitled to receive or receives any payment or benefit under this Agreement or under any other plan, agreement or arrangement with the Company, or any person whose
actions result in a Change in Control or any other person affiliated with the Company or such person (all such payments and benefits being referred to herein as the “Total Payments”) and it is determined that any of the Total Payments will
be subject to any excise tax pursuant to Section 4999 of the Code, or any similar or successor provision (the “Excise Tax”), the Company shall pay to Executive an additional amount as a gross-up (the “Gross Up Payment”). The
Gross-Up Payment shall be an amount such that, after payment by the Executive of all taxes (including any interest or penalties imposed with respect to such taxes), including any Excise Tax imposed upon the Gross-Up Payment, the Executive retains an
amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Total Payments. For purposes of determining the amount of the Gross-Up Payment, the Executive will be considered to pay (x) federal income taxes at the highest rate in
effect in the year in which the Gross-Up Payment will be made and (y) state and local income taxes at the highest rate in effect in the state or locality in which the Gross-Up Payment would be subject to state or local tax, net of the maximum
reduction in federal income tax that could be obtained from deduction of such state and local taxes. The Gross-Up Payment, if any, shall be paid no later than sixty (60) days following the Change in Control. 

(b) All computations and determinations called for by this Section 4 shall be made by an independent public accounting firm or
independent tax counsel appointed by the Company (the “Firm”). All determinations made by the Firm under this Section 4 shall be conclusive and binding on both the Company and Executive, and the Firm shall provide its determinations
and any supporting calculations to the Company and Executive within at least ten (20) business days preceding the date of the Change in Control, or such earlier time as is requested by the Company. For purposes of making its determinations
under this Section 4, the Firm may rely on reasonable, good faith interpretations concerning the application of Code Sections 280G and 4999. The Company and Executive shall furnish to the Firm such information and documents as the Firm may
reasonably request in making its determinations. The Company shall bear all fees and expenses charged by the Firm in connection with its services. 
 5. Section 409A. It is the intent of the parties hereto that the Severance Compensation is exempt from Section 409A of the Code pursuant to Treas. Reg. §1.409A-1(b)(4). In the event
that the Severance Compensation constitutes “non-qualified deferred compensation” within the meaning of Section 409A, then the following rules shall apply: 
 (a) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of amounts or benefits upon or following a termination of
employment unless such termination constitutes a “separation from service” within the meaning of Treas. Reg. § 1.409A-1(h)(1), without regard to the optional alternative definitions available thereunder (a “Separation from
Service”), and, for purposes of any such provision of this Agreement, references to “terminate,” “termination,” “termination of employment,” “resigns” and like terms shall mean Separation from Service.

  

Initials      

 (b) If Executive is a “specified employee” within the meaning of Treas. Reg.
§ 1.409A-1(i) as of the date of Executive’s Separation from Service, Executive shall not be entitled to any payment or benefit on account of Executive’s Separation from Service, until the earlier of (1) the date which is six
(6) months after Executive’s Separation from Service for any reason other than death or (2) the date of Executive’s death. The provisions of this paragraph shall only apply if, and to the extent, required to avoid the imputation
of any tax, penalty or interest pursuant to Section 409A on Executive. Any amounts otherwise payable to Executive upon or in the six (6) month period following Executive’s Separation from Service that are not so paid by reason of this
Section 5 shall be paid (without interest) as soon as practicable (and in all events within thirty (30) days) after the date that is six (6) months after Executive’s Separation from Service (or, if earlier, as soon as
practicable, and in all events within thirty (30) days, after the date of Executive’s death). 
 6. No Duplication of
Compensation. The Severance Compensation shall replace, and be provided in lieu of, any severance compensation that may be provided to the Executive under any other agreement, provided, however, that this prohibition against duplication shall
not be construed to otherwise limit the Executive’s rights as to payments or benefits provided under any pension plan (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended), deferred compensation,
stock, stock option or similar plan sponsored by the Company. 
 7. Enforceability. If any provision of this Agreement shall be deemed
invalid or unenforceable as written, this Agreement shall be construed, to the greatest extent possible, or modified, to the extent allowable by law, in a manner which shall render it valid and enforceable. No invalidity or unenforceability of any
provision contained herein shall affect any other portion of this Agreement. 
 8. Notices. All notices, requests, consents and other
communications hereunder shall be in writing, shall be addressed to the receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be either (i) delivered by hand,
(ii) made by facsimile transmission, (iii) sent by overnight courier, or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. 
 If to the Company: 
 Amedica Corporation 

Attn: Chief Legal Officer 
 1885 West 2100 South 
 Salt lake City, UT 84119 

Facsimile: (801)839-3500 
 If to the Executive: 
 To the Executive’s last-known home address and/or
facsimile number as set forth in the Company’s personnel records 

  

Initials      

 All notices, requests, consents and other communications hereunder shall be deemed to have been given either
(i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by facsimile transmission, at the time that receipt thereof has been acknowledged by electronic
confirmation or otherwise, (iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the 5th business day following
the day such mailing is made. 
 9. Entire Agreement. This Agreement, together with the other agreements referenced herein, embodies the
entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation,
warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 

10. Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the
Company and the Executive. 
 11. Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the
departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other
terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

 12. Binding Effect; Assignment. The Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal
representatives of the Executive upon the Executive’s death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of the Agreement for all purposes. For this
purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the
Company. None of the rights of the Executive to receive any form of compensation payable pursuant to the Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer,
conveyance or other disposition of the Executive’s right to compensation or other benefits will be null and void. 
 13. Governing
Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the law of the State of Utah, without giving effect to the conflict of law principles thereof. 

14. Jurisdiction and Service of Process. Any legal action or proceeding with respect to this Agreement shall be brought in the courts of the State
of Utah or of the United States of America for the District of Utah. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the
aforesaid courts. Each of the parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its
address set forth in Section 8 hereof. 

  

Initials      

 15. No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any
right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this
Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy
hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the
party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances
without such notice or demand. 
 16. Withholding. The Company is authorized to withhold, or cause to be withheld, from any payment or
benefit under the Agreement the full amount of any applicable withholding taxes. 
 17. Tax Consequences. The Company does not guarantee
the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement. 
 18. Acknowledgment. The
Executive acknowledges that he has had the opportunity to discuss this matter with and obtain advice from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of the Agreement, and is
knowingly and voluntarily entering into the Agreement. 
 19. Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 IN WITNESS
WHEREOF, the parties have executed this Agreement as of the day and year first above written. 
  

			
	COMPANY:
	
	AMEDICA CORPORATION
		
	By:	 	 
	Name: Eric Olson
	Title: Chief Executive Officer
	
	EXECUTIVE:
	
	 
	[•]

  

Initials

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]